2-ethyl 4-methyl 5-formyl-3-methyl-1H-pyrrole-2,4-dicarboxylate | 517883-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 2-ethyl 4-methyl 5-formyl-3-methyl-1H-pyrrole-2,4-dicarboxylate
• 英文别名: 2-O-ethyl 4-O-methyl 5-formyl-3-methyl-1H-pyrrole-2,4-dicarboxylate
• CAS: 517883-10-2
• 化学式: C₁₁H₁₃NO₅
• 分子量: 239.228
• InChiKey: OLRVPDCGCCBSRZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  85.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-ethyl 4-methyl 5-formyl-3-methyl-1H-pyrrole-2,4-dicarboxylate 、 乙酰基乙酰对氯苯胺 、 尿素 在 乳酸 作用下， 反应 0.83h， 以80%的产率得到
  参考文献：
  名称：

  Solvothermal Synthesis of Multiple Dihydropyrimidinones at a Time as Inhibitors of Eg5

  摘要：

  在廉价且绿色的生物基溶剂乳酸中，已经开发出一种同时合成多个二氢嘧啶酮的溶剂热合成方法，无需任何额外的催化剂或添加剂。通过这种方法，已经合成并表征了30种新的二氢嘧啶酮衍生物。所有化合物均通过Eg5马达蛋白ATP酶活性分析进行筛选，并对阳性化合物进行了体外针对Caco-2细胞系、HeLa细胞系、L929细胞系和T24细胞系的测试。其中，化合物C9对马达蛋白ATP酶表现出最佳的抑制活性，IC50值为30.25 μM，并在微摩尔范围内对上述细胞表现出显著的细胞毒性活性。Lineweaver–Burk图表明，化合物C9是一种混合型Eg5抑制剂。使用Discovery Studio程序进行的分子建模研究显示，化合物C9与Eg5马达蛋白ATP酶有良好的结合相互作用，与实验结果一致。

  DOI：

  10.3390/molecules26071925

文献信息

• ANTIBODIES
  申请人：Sathyanarayanan Sriram

  公开号：US20120058112A1

  公开（公告）日：2012-03-08

  The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.

  本发明描述了IGF-1R拮抗剂（例如人源化抗体）和抗增殖药物的组合。在一种优选实施方案中，本发明描述了IGF-1R抗体和属于EGFR抑制剂类的抗增殖药物（优选为厄洛替尼）的组合。根据本发明的组合对于治疗肿瘤，包括IGF-1R和/或EGFR介导或依赖的肿瘤是有用的。
• Methods and Compositions for Treating or Preventing Cancer
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150093398A1

  公开（公告）日：2015-04-02

  This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.

  本发明涉及用于治疗各种癌症的组合物和方法。本申请还涵盖了治疗组合物和使用方法。
• [EN] TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE
  申请人：MERCK & CO INC

  公开号：WO2003035614A2

  公开（公告）日：2003-05-01

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a 2-carboxy-5-formyl pyrrole. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.
• Solvothermal Synthesis of Multiple Dihydropyrimidinones at a Time as Inhibitors of Eg5
  作者：Xiao-Qiang Jiang、Shi-Quan Chen、Yan-Fei Liu、Xin-Guang Pan、Dan Chen、Shi-Fan Wang

  DOI：10.3390/molecules26071925

  日期：——

  Solvothermal synthesis of multiple dihydropyrimidinones at a time has been developed in inexpensive and green bio-based solvent lactic acid without any additional catalysts or additives. By this method, thirty new dihydropyrimidinone derivatives were synthesized in two batches and characterized. All of the compounds were screened by Eg5 motor protein ATPase assay, and the positive compounds were tested against the Caco-2 cell line, HeLa cell line, L929 cell line and T24 cell line in vitro. Among them, compound C9 exhibited the best inhibitory activity against motor protein ATPase with an IC50 value of 30.25 μM and significant cytotoxic activity in the micromolar range against the cells above. The Lineweaver–Burk plot revealed that compound C9 was a mixed-type Eg5 inhibitor. A molecular modeling study using the Discovery Studio program was performed, where compound C9 exhibited good binding interaction with Eg5 motor protein ATPase, and this was consistent with the attained experimental results.

  在廉价且绿色的生物基溶剂乳酸中，已经开发出一种同时合成多个二氢嘧啶酮的溶剂热合成方法，无需任何额外的催化剂或添加剂。通过这种方法，已经合成并表征了30种新的二氢嘧啶酮衍生物。所有化合物均通过Eg5马达蛋白ATP酶活性分析进行筛选，并对阳性化合物进行了体外针对Caco-2细胞系、HeLa细胞系、L929细胞系和T24细胞系的测试。其中，化合物C9对马达蛋白ATP酶表现出最佳的抑制活性，IC50值为30.25 μM，并在微摩尔范围内对上述细胞表现出显著的细胞毒性活性。Lineweaver–Burk图表明，化合物C9是一种混合型Eg5抑制剂。使用Discovery Studio程序进行的分子建模研究显示，化合物C9与Eg5马达蛋白ATP酶有良好的结合相互作用，与实验结果一致。